Antibody Discovery Market to Reach USD 15.45 Billion by 2030, Driven by Growing Biologics Demand and AI-Driven Platforms

Mordor Intelligence has published a new report on antibody discovery market offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The antibody discovery market size stands at USD 9.09 billion in 2025 and is projected to reach USD 15.45 billion by 2030, translating into an 11.3% CAGR across the forecast period.

This growth reflects shifting priorities within pharmaceutical and biotech development. As more companies prioritize biologics over small-molecule drugs particularly in areas such as oncology, immunology, and chronic diseases demand for novel antibodies is rising sharply. Advances in screening and design technologies, as well as changes in regulatory environment and patent expirations of older therapies, are helping drive growth in the antibody discovery market.

Report Overview:

https://www.mordorintelligence.com/industry-reports/antibody-discovery-market?utm_source=openpr

Key Trends in Antibody Discovery Market

Rising Demand for Monoclonal Antibody Therapeutics

Therapeutic antibodies have become central to modern medicine. Over 200 antibody products are currently marketed, and many of them remain highly successful. This success continues to prompt investment into new antibody discovery programs especially in oncology, autoimmune diseases, infectious diseases, and neurology. The late-stage pipelines are broadening: a substantial portion of new candidates address cancer, while a significant share targets immune-mediated conditions.

Technological Advances: Phage Display, Single-B-Cell Screening, and AI/ML-Driven Design

Traditional methods like hybridoma technology have formed the foundation of antibody discovery, but newer technologies are changing the landscape. Phage display and single-B-cell screening now allow antibody generation against challenging targets, such as membrane proteins or conformational epitopes targets that hybridoma methods often struggle with.

Increasing Outsourcing to Contract Discovery and CDMO Services

As antibody discovery becomes more complex and capital intensive, many firms especially small and mid-sized biotechs are turning away from in-house discovery. Instead, they leverage contract research organizations and CDMOs for discovery services. This reduces upfront investment in infrastructure and accelerates timelines.

Regulatory and Patent-Driven "Follow-On" Opportunities

As several early-generation monoclonal antibodies near patent expiry, the door opens for follow-on or next-generation antibodies. Regulatory agencies have issued guidance for non-traditional formats such as bispecific and multispecific antibodies improving clarity around development pathways. These factors combined make the antibody discovery market more attractive and less risky for investors.

Market Segmentation in the Antibody Discovery Market

The antibody discovery market can be understood by examining several key segmentation categories:

By Discovery Technology

Hybridoma Technology

Phage Display

Single-B-Cell Screening

Transgenic Animal Platforms

Yeast Display

Mammalian / Ribosome Display

AI/ML-Enabled In-Silico Design

By Service Model

In-house Discovery

Contract / Outsourced Discovery Services

Hybrid Co-development Partnerships

By End User

Pharmaceutical & Biopharmaceutical Companies

Biotechnology Start-ups

Academic & Research Institutes

Contract Research Organizations (CROs)

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

This segmentation outlines how different technologies, business models, and global regions contribute to the overall antibody discovery market size and dynamics. The variety of approaches from traditional hybridoma to cutting-edge computational design ensures that demand remains diversified and resilient.

Key Players in the Antibody Discovery Market

The competitive landscape of the antibody discovery market features a mix of large, established life-science companies as well as specialized, nimble entrants:

GenScript Biotech

WuXi Biologics

Abcam plc

Thermo Fisher Scientific

Cytiva (Danaher)

This mixture of large incumbents and nimble specialists contributes to a moderately fragmented but dynamic competitive landscape. The diversity of company strategies from full-service offerings to lean computational platforms enhances competition and supports rapid innovation across the antibody discovery market.

Conclusion

The global antibody discovery market is entering a phase of strong growth, with the projected value rising from USD 9.09 billion in 2025 to USD 15.45 billion by 2030. This growth is underpinned by rising demand for monoclonal antibodies, increasing use of advanced discovery technologies (including AI/ML), and broader adoption of outsourced discovery services.

As therapeutic antibodies continue to expand into new disease areas including cancer, immune disorders, and chronic diseases the need for novel antibody candidates grows. Advances in phage display, single-cell screening, and computational design are helping meet these needs more efficiently than ever before.

For complete market analysis, please visit the Mordor Intelligence page:

https://www.mordorintelligence.com/industry-reports/antibody-discovery-market?utm_source=openpr

Industry related Reports:

Custom Antibody Market: The Custom Antibody Market Report provides forecasts in terms of value (USD) and covers a comprehensive segmentation that includes antibody type such as monoclonal antibodies, polyclonal antibodies, and others along with services like antibody development, production, and purification. It also examines key application areas including oncology, infectious diseases, neurology, and more, while profiling major end users such as pharmaceutical and biotechnology companies. Additionally, the report analyzes the market across major geographic regions including North America, Europe, and other global markets.

Get more Insights: https://www.mordorintelligence.com/industry-reports/custom-antibody-market?utm_source=openpr

Antibody Fragments Market : The Antibody Fragments Market Report provides an overview of the industry by outlining key segmentation parameters, including fragment type (such as Fab, ScFv, dual-fragment formats, and others), application areas (therapeutics, diagnostics and imaging, among others), production methods (bacterial, yeast, mammalian, and more), and end-user categories (biopharmaceutical companies, CROs/CMOs, and others). The analysis also covers regional markets across North America, Europe, Asia Pacific, the Middle East & Africa, and South America, with all market forecasts presented in terms of value (USD).

Get more Insights: https://www.mordorintelligence.com/industry-reports/antibody-fragments-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.